eqtventures

Tomorrow's company, myTomorrows

Kees Koolen

EQT Ventures is happy to welcome myTomorrows to the family. myTomorrows was founded to improve access to drugs in development for physicians and their patients facing an unmet medical need. myTomorrows announces a €10m growth funding round, co-led by EQT Ventures and Octopus Ventures.

Founded to improve access to drugs in development for physicians and their patients, myTomorrows announces a €10m growth funding round, co-led by EQT Ventures and Octopus Ventures, with participation from existing investors Balderton Capital and Sofinnova Partners.

myTomorrows’ name is inspired from having another tomorrow, another day to live. The company has built a platform that gives transparency and easy access to physicians and their patients to discover and procure so called early-access programs, and navigate data from over 300,000 ongoing and historic clinical trials. Today, a complicated international landscape of regulations and processes makes accessing the right program at the right time very complex - this is what myTomorrows aims to solve.

“Combining deep medical, technological and regulatory expertise, we have proven that the marketplace model for accessing drugs in development works - for physicians and their patients, for drug makers, even for governments. Where patients are facing an unmet medical need, we see our role in breaking down barriers and making access to promising drugs possible” said Roland Brus MD, Founder and CEO of myTomorrows. “The way medicines are developed today is changing. We will see the collection of efficacy data move out of an artificial clinical setting and into the real world, treating regular patients. Focusing on creating access for the large group of patients that cannot participate in clinical trials, the myTomorrows concept will play a key role in the development of real-world evidence collection”

“myTomorrows is a great fit for EQT Ventures. It has the opportunity to genuinely disrupt an industry, and solve a problem which could change many people’s lives. The team has incredible drive and deep expertise across medicine, biotech and technology. In an era where information asymmetry has been removed by the internet, myTomorrows has created a digital marketplace connecting physicians with drug developers under the watchful eye of local regulators, in order to provide access to drugs that might otherwise be out of reach for patients who have run out of other treatment options.” said Kees Koolen, Founding Partner at EQT Ventures.

Read full press release here - https://www.mytomorrows.com/2017